Apg990 Interim Phase 1 Results Show Potential for Maintenance Dosing
Apogee Therapeutics announced positive interim Phase 1 results for APG990, a novel, half-life extended OX40L antibody, demonstrating an approximately...
Lexicon Announces Pilavapan Results for Diabetic Nerve Pain
Lexicon Pharmaceuticals will announce topline results from its Phase 2b PROGRESS study of pilavapadin (LX9211) for diabetic peripheral neuropathic...
Y-mAbs Phase 2 Results Published in Nature Communications
Y-mAbs Therapeutics announced interim Phase 2 trial data published in Nature Communications, showing naxitamab combined with GM-CSF is effective...
Key Takeaways from SCOPE Summit 2025: Budget Negotiations, Protocol Design, and AI in Clinical TrialsSCOPE Summit Summary
The SCOPE Summit 2025 addressed key areas in clinical trials: budget negotiations, protocol design, and AI integration. Clinical Trial...
DM Clinical Research Data Breach Exposes Over 1.6M Records, Raising Patient Privacy Concerns
DM Clinical Research, a Texas-based clinical trial site network, has suffered a major data breach, exposing over 1.6 million...
Seoul Semiconductor’s Natural Light Revolutionizes Lighting
Seoul Semiconductor will showcase its SunLike LED technology, designed to mimic natural light, at JAPAN SHOP 2025 in Tokyo....
Milestone Reached: First Patient Treated with EG110A for Neurogenic Bladder
EG 427 has dosed the first patient in its Phase 1b/2a clinical trial of EG110A, a novel gene therapy...
Derm-Biome’s DB-007-5 Highly Effective in Atopic Dermatitis Study
Derm-Biome Pharmaceuticals announced positive preclinical results for its topical drug DB-007-5 in treating atopic dermatitis (AD). The drug significantly...
Sonnet BioTherapeutics Son-1010: Improved Solid Tumor Treatment
Sonnet BioTherapeutics presented data at the 2025 AACR:IO Conference on its Fully Human Albumin Binding (FHAB) platform, which enhances...
First Participant Dosed in Phase 1a Study of Oral HDV Entry Inhibitor
Assembly Biosciences has dosed the first participant in a Phase 1a clinical trial for ABI-6250, an oral HDV entry...